Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Director Grace Patrick P. of CHEMED CORP (NYSE:CHE) sold 150 shares of Capital Stock on September 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $463.39, for a total transaction value of $69,508. The $6.58 billion healthcare company maintains excellent financial health, earning a "GREAT" rating according to InvestingPro analysis.
Following the transaction, Grace Patrick P. directly owns 3397 shares of the company. While this insider sale occurred, InvestingPro data shows management has been actively buying back shares, and the company has maintained dividend payments for 55 consecutive years. Discover more insights about CHE’s valuation and growth potential with InvestingPro’s comprehensive research report, available along with 7 additional key ProTips.
In other recent news, Chemed Corporation’s second-quarter 2025 earnings did not meet analyst expectations, reporting earnings per share of $4.27, which was below the anticipated $5.39. Revenue also fell short, coming in at $618.8 million compared to the projected $650.6 million. In a separate development, Jefferies upgraded Chemed’s stock rating from Hold to Buy, raising the price target from $490.00 to $550.00, citing favorable Medicare reimbursement as a key factor. Additionally, VITAS Healthcare, a subsidiary of Chemed, announced that Nicholas M. Westfall will step down as CEO to pursue other opportunities. Joel L. Wherley, previously president and COO, will take over as CEO. These developments reflect significant changes and challenges for Chemed as it navigates through the current fiscal year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.